Ibero-American Consensus Review and Incorporation of New Biomarkers for Clinical Practice in Colorectal Cancer

• Published in: Cancers Vol. 15; no. 17; p. 4373
• Main Authors: Bonilla, Carlos Eduardo, Montenegro, Paola, O’Connor, Juan Manuel, Hernando-Requejo, Ovidio, Aranda, Enrique, Pinto Llerena, José, Llontop, Alejandra, Gallardo Escobar, Jorge, Díaz Romero, María del Consuelo, Bautista Hernández, Yicel, Graña Suárez, Begoña, Batagelj, Emilio J, Wali Mushtaq, Ahmad, García-Foncillas, Jesús
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01-09-2023; MDPI
• Subjects: Antigens; Biological markers; Biomarkers; Biopsy; Cancer; Cancer therapies; Chemotherapy; Classification; Clinical medicine; Colorectal cancer; Colorectal carcinoma; Cytotoxicity; Genetic testing; Histopathology; Immunotherapy; Lymphocytes; Medical prognosis; Metastasis; Mutation; Next-generation sequencing; Oncology; Patients; Polymerase chain reaction; Review; Tumors; Argentina; Spain
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers15174373

Advances in genomic technologies have significantly improved the management of colorectal cancer (CRC). Several biomarkers have been identified in CRC that enable personalization in the use of biologic agents that have shown to enhance the clinical outcomes of patients. However, technologies used for their determination generate massive amounts of information that can be difficult for the clinician to interpret and use adequately. Through several discussion meetings, a group of oncology experts from Spain and several Latin American countries reviewed the latest literature to provide practical recommendations on the determination of biomarkers in CRC based on their clinical experience. The article also describes the importance of looking for additional prognostic biomarkers and the use of histopathology to establish an adequate molecular classification. Present and future of immunotherapy biomarkers in CRC patients are also discussed, together with several techniques for marker determination, including liquid biopsy, next-generation sequencing (NGS), polymerase chain reaction (PCR), and fecal immunohistochemical tests. Finally, the role of Molecular Tumor Boards in the diagnosis and treatment of CRC is described. All of this information will allow us to highlight the importance of biomarker determination in CRC.